Biocon's first-in-class anti-CD6 mAb reaches the market

@article{Jayaraman2013BioconsFA,
  title={Biocon's first-in-class anti-CD6 mAb reaches the market},
  author={K. Jayaraman},
  journal={Nature Biotechnology},
  year={2013},
  volume={31},
  pages={1062-1063}
}
The Italian government withdrew its support for a controversial stem cell therapy trial before it was due to start, prompting an outcry from patients. The decision was announced by Health Minister Beatrice Lorenzin on October 10, after an ad hoc scientific committee deemed the treatment too risky and undefined. In May, and bowing to public pressure, the government allocated €3 ($3.9) million to support a clinical trial of the method developed by the Bresciabased nonprofit Stamina Foundation and… CONTINUE READING